These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 20110538)

  • 1. Coronary heart disease risk in patients with stroke or transient ischemic attack and no known coronary heart disease: findings from the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
    Amarenco P; Goldstein LB; Sillesen H; Benavente O; Zweifler RM; Callahan A; Hennerici MG; Zivin JA; Welch KM;
    Stroke; 2010 Mar; 41(3):426-30. PubMed ID: 20110538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atorvastatin reduces the risk of cardiovascular events in patients with carotid atherosclerosis: a secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
    Sillesen H; Amarenco P; Hennerici MG; Callahan A; Goldstein LB; Zivin J; Messig M; Welch KM;
    Stroke; 2008 Dec; 39(12):3297-302. PubMed ID: 18845807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of stroke and cardiovascular events after ischemic stroke or transient ischemic attack in patients with type 2 diabetes or metabolic syndrome: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
    Callahan A; Amarenco P; Goldstein LB; Sillesen H; Messig M; Samsa GP; Altafullah I; Ledbetter LY; MacLeod MJ; Scott R; Hennerici M; Zivin JA; Welch KM;
    Arch Neurol; 2011 Oct; 68(10):1245-51. PubMed ID: 21670382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of high-dose atorvastatin on renal function in subjects with stroke or transient ischemic attack in the SPARCL trial.
    Amarenco P; Callahan A; Campese VM; Goldstein LB; Hennerici MG; Messig M; Sillesen H; Welch KM; Wilson DJ; Zivin JA
    Stroke; 2014 Oct; 45(10):2974-82. PubMed ID: 25147328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Baseline blood pressure, low- and high-density lipoproteins, and triglycerides and the risk of vascular events in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
    Amarenco P; Goldstein LB; Callahan A; Sillesen H; Hennerici MG; O'Neill BJ; Rudolph AE; Simunovic L; Zivin JA; Welch KM;
    Atherosclerosis; 2009 Jun; 204(2):515-20. PubMed ID: 18962621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial by stroke subtypes.
    Amarenco P; Benavente O; Goldstein LB; Callahan A; Sillesen H; Hennerici MG; Gilbert S; Rudolph AE; Simunovic L; Zivin JA; Welch KM;
    Stroke; 2009 Apr; 40(4):1405-9. PubMed ID: 19228842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atorvastatin: its clinical role in cerebrovascular prevention.
    Gaspardone A; Arca M
    Drugs; 2007; 67 Suppl 1():55-62. PubMed ID: 17910521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack: the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
    Amarenco P; Goldstein LB; Szarek M; Sillesen H; Rudolph AE; Callahan A; Hennerici M; Simunovic L; Zivin JA; Welch KM;
    Stroke; 2007 Dec; 38(12):3198-204. PubMed ID: 17962589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose atorvastatin after stroke or transient ischemic attack.
    Amarenco P; Bogousslavsky J; Callahan A; Goldstein LB; Hennerici M; Rudolph AE; Sillesen H; Simunovic L; Szarek M; Welch KM; Zivin JA;
    N Engl J Med; 2006 Aug; 355(6):549-59. PubMed ID: 16899775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of atorvastatin in elderly patients with a recent stroke or transient ischemic attack.
    Chaturvedi S; Zivin J; Breazna A; Amarenco P; Callahan A; Goldstein LB; Hennerici M; Sillesen H; Rudolph A; Welch MA;
    Neurology; 2009 Feb; 72(8):688-94. PubMed ID: 18768917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and baseline characteristics of the stroke prevention by aggressive reduction in cholesterol levels (SPARCL) study.
    Amarenco P; Bogousslavsky J; Callahan AS; Goldstein L; Hennerici M; Sillsen H; Welch MA; Zivin J;
    Cerebrovasc Dis; 2003; 16(4):389-95. PubMed ID: 14584489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose atorvastatin and risk of atrial fibrillation in patients with prior stroke or transient ischemic attack: analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial.
    Schwartz GG; Chaitman BR; Goldberger JJ; Messig M
    Am Heart J; 2011 May; 161(5):993-9. PubMed ID: 21570534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of major vascular events after stroke: the stroke prevention by aggressive reduction in cholesterol levels trial.
    Ovbiagele B; Goldstein LB; Amarenco P; Messig M; Sillesen H; Callahan A; Hennerici MG; Zivin J; Welch KM;
    J Stroke Cerebrovasc Dis; 2014 Apr; 23(4):778-84. PubMed ID: 24582273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oxidized Phospholipids on Apolipoprotein B-100 and Recurrent Ischemic Events Following Stroke or Transient Ischemic Attack.
    Byun YS; Yang X; Bao W; DeMicco D; Laskey R; Witztum JL; Tsimikas S;
    J Am Coll Cardiol; 2017 Jan; 69(2):147-158. PubMed ID: 28081824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relative and cumulative effects of lipid and blood pressure control in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels trial.
    Amarenco P; Goldstein LB; Messig M; O'Neill BJ; Callahan A; Sillesen H; Hennerici MG; Zivin JA; Welch KM;
    Stroke; 2009 Jul; 40(7):2486-92. PubMed ID: 19461031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review of the SPARCL trial and its subanalyses.
    Welch KM
    Curr Atheroscler Rep; 2009 Jul; 11(4):315-21. PubMed ID: 19500496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atorvastatin in prevention of stroke and transient ischaemic attack.
    Amarenco P
    Expert Opin Pharmacother; 2007 Nov; 8(16):2789-97. PubMed ID: 17956199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atorvastatin Reduces First and Subsequent Vascular Events Across Vascular Territories: The SPARCL Trial.
    Szarek M; Amarenco P; Callahan A; DeMicco D; Fayyad R; Goldstein LB; Laskey R; Sillesen H; Welch KM;
    J Am Coll Cardiol; 2020 May; 75(17):2110-2118. PubMed ID: 32194196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose statin therapy for secondary prevention of stroke: stroke prevention by aggressive reduction in cholesterol levels study review.
    Schwertz DW; Badellino KO
    J Cardiovasc Nurs; 2008; 23(1):8-13. PubMed ID: 18158500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relative effects of statin therapy on stroke and cardiovascular events in men and women: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study.
    Goldstein LB; Amarenco P; Lamonte M; Gilbert S; Messig M; Callahan A; Hennerici M; Sillesen H; Welch KM;
    Stroke; 2008 Sep; 39(9):2444-8. PubMed ID: 18617654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.